TICKERNERD
Menu
COCPCOCPHealthcare · Biotechnology

COCP Stock Forecast: Cocrystal Pharma, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.24
+0.81% on the day

The 1 Wall Street analysts covering Cocrystal Pharma, Inc. hold a median 12-month price target of $9 — +625.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 12 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$23.9M
Ticker Nerd rank
71 / 100
Median analyst target
$9.00
Analysts covering
1
Revenue$105K
Operating income−$3.2M
Net income−$3.2M
Free cash flow−$2.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+9.7%
1M
+14.8%
YTD
+26.5%
1Y
−13.9%
From 52W high
−21.5%
From 52W low
+51.2%
$0.82
$1.58
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

COCP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cocrystal Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
71 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
87
Size
87
Revisions
70
Issuance
65
Volatility
62
Value
51
Growth
47
Momentum
43
Quality
20

Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (20): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

COCP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COCP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26COCPHigh $10.00Median $9.00Low $8.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $8.00Median $9.00High $10.00

The green dot is the last close — the median target sits +625.8% from it.

Recent analyst actionsNewest first

Of the 18 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
20 June 2025HC Wainwright & Co.MaintainsBuy$7.00 → $6.00
22 Jan 2025HC Wainwright & Co.ReiteratesBuy—
22 Aug 2024HC Wainwright & Co.MaintainsBuy$10 → $7.00
14 May 2024HC Wainwright & Co.ReiteratesBuy—
4 Apr 2024HC Wainwright & Co.ReiteratesBuy—
20 Mar 2024HC Wainwright & Co.ReiteratesBuy—
3 Jan 2024HC Wainwright & Co.MaintainsBuy—
4 Dec 2023HC Wainwright & Co.ReiteratesBuy—
4 Oct 2023HC Wainwright & Co.ReiteratesBuy—
15 Aug 2023HC Wainwright & Co.ReiteratesBuy—
11 Aug 2023HC Wainwright & Co.ReiteratesBuy—
2 June 2023HC Wainwright & Co.ReiteratesBuy—
24 May 2023HC Wainwright & Co.MaintainsBuy—
24 Jan 2023HC Wainwright & Co.MaintainsBuy—
7 Nov 2022HC Wainwright & Co.MaintainsBuy—
12 Nov 2020HC Wainwright & Co.MaintainsBuy$5.00 → $4.50
8 July 2020HC Wainwright & Co.InitiatesBuy—
16 June 2020Noble Capital MarketsInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. COCP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

COCP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Cocrystal Pharma, Inc. returned −13.9% against +17.5% for the S&P 500, dividends included.

COCP vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26COCPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

COCP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Cocrystal Pharma, Inc. (COCP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.6×

Cheaper than 84% of US stocks

Price / sales
72.4×

Cheaper than 5% of US stocks

Price / book
16.3×

Cheaper than 6% of US stocks

EV / EBITDA
−2.3×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
−53.3%

Higher than 5% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−3032.4%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−311.7%

Higher than 5% of US stocks

Return on assets
−96.1%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cocrystal Pharma, Inc. (COCP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cocrystal Pharma, Inc. has a market value of $23.9M and an enterprise value of $23.1M.

  • Revenue in the twelve months to 30 June 2026: $330K. The latest quarter shrank 53.3% year on year.

  • Net income over the same four quarters: −$9.9M, a −3011.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$8.0M.

  • Shares outstanding: 13.8M.

  • Trailing P/E: −1.6×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Cocrystal Pharma, Inc. employs 10 people — $33K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

COCP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
COCPCocrystal Pharma, Inc.$23.9M
71
TVRDTvardi Therapeutics, Inc.$24.9M
29
ATOSAtossa Therapeutics, Inc.$25.0M
24
ACTUActuate Therapeutics, Inc.$25.7M
31
QNTMQuantum BioPharma Ltd.$25.9M
41
NNVCNanoViricides, Inc.$25.9M
58
JSPRJasper Therapeutics, Inc.$22.0M
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cocrystal Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest COCP news & analysis

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

GlobeNewsWire · 9 Sept 2026positive

Cocrystal Pharma announced that the last subject has been dosed in its Phase 1b human challenge study evaluating CDI-988 for norovirus prevention and treatment. To date, no serious adverse events have been reported, and preliminary efficacy results are expected in late 2026 or early 2027.

Why it matters — This marks a key milestone in the clinical development of CDI-988, with preliminary efficacy data expected in roughly two years, giving COCP watchers a timeline for a potential catalyst.

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

GlobeNewsWire · 17 Aug 2026positive

Cocrystal Pharma, Inc. announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, and biopharma advisory to the company's board.

Why it matters — A COCP watcher would care because adding a director with deep expertise in antiviral therapy and epidemiology aligns with the company's focus on developing antiviral treatments.

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

GlobeNewsWire · 3 Aug 2026positive

Cocrystal Pharma announced a $5 million investment from longtime investor OPKO Health, increasing OPKO's position as Cocrystal advances its lead norovirus program toward Phase 1b topline data later this year.

Why it matters — The private placement provides additional funding and reinforces backing from a longtime investor as Cocrystal approaches a key clinical data readout for its norovirus program.

FAQ

Frequently asked questions about COCP stock

What is the COCP stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Cocrystal Pharma, Inc. have a median 12-month price target of $9, with estimates ranging from $8 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is COCP stock a buy right now?

Of the 1 analysts covering Cocrystal Pharma, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cocrystal Pharma, Inc. 71 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank COCP?

As at 12 Sept 2026, Cocrystal Pharma, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).

Will COCP stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +625.8% from the last close, and Ticker Nerd's factor model ranks Cocrystal Pharma, Inc. 71 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the COCP stock forecast for 2030?

No analyst covering Cocrystal Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COCP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $10 over the next 12 months.

How has COCP stock performed over the past year?

Cocrystal Pharma, Inc. returned -13.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cocrystal Pharma, Inc. do?

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics for serious viral diseases.

What is the latest news on COCP?

The most recent item we track (GlobeNewsWire, 9 Sept 2026): "Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment". Cocrystal Pharma announced that the last subject has been dosed in its Phase 1b human challenge study evaluating CDI-988 for norovirus prevention and treatment. To date, no serious adverse events have been reported, and preliminary efficacy results are expected in late 2026 or early 2027.

Company

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics for serious viral diseases. The company’s current programs target the replication mechanisms of norovirus, influenza, coronaviruses, and hepatitis C, with an emphasis on oral direct-acting candidates designed for treatment and prevention settings. Its pipeline includes drug development efforts that span discovery, preclinical work, and clinical-stage studies, supported by structure-based technologies aimed at identifying differentiated antiviral compounds. Cocrystal Pharma also engages in research partnerships and funding activities that help advance its antiviral portfolio and related scientific programs. Headquartered in Bothell, Washington, Cocrystal Pharma plays a specialized role in the biotechnology market by addressing unmet needs in infectious disease therapeutics through targeted antiviral innovation.

CEO Dr. Sam Lee Ph.D. · 10 employees · United States · https://www.cocrystalpharma.com